Key Points
- A/S Genmab bought 66,264 shares of Merus on Dec. 19 at $97 each (about $6.43M) and, including purchases on Dec. 16–18, acquired a total of 549,988 shares (~$53.35M), raising its stake to 72,013,065 shares — a 0.09% increase valued at roughly $6.99B.
- Merus trades near its 12‑month high (~$97) with a market cap of $7.35B, 96.14% institutional ownership, and a consensus analyst rating of Hold with an average price target of $93.56.
Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab acquired 66,264 shares of Merus stock in a transaction on Friday, December 19th. The shares were purchased at an average price of $97.00 per share, with a total value of $6,427,608.00. Following the completion of the purchase, the insider owned 72,013,065 shares in the company, valued at $6,985,267,305. This represents a 0.09% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
A/S Genmab also recently made the following trade(s):
- On Thursday, December 18th, A/S Genmab bought 212,177 shares of Merus stock. The stock was purchased at an average price of $97.00 per share, for a total transaction of $20,581,169.00.
- On Wednesday, December 17th, A/S Genmab purchased 150,795 shares of Merus stock. The shares were purchased at an average price of $97.00 per share, for a total transaction of $14,627,115.00.
- On Tuesday, December 16th, A/S Genmab purchased 120,752 shares of Merus stock. The shares were purchased at an average cost of $97.00 per share, with a total value of $11,712,944.00.
Merus Stock Down 0.1%
Shares of NASDAQ MRUS opened at $96.95 on Tuesday. The firm has a market cap of $7.35 billion, a P/E ratio of -18.29 and a beta of 1.06. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $97.14. The company has a 50 day moving average of $95.71 and a 200 day moving average of $76.34.
Institutional Investors Weigh In On Merus
A number of large investors have recently made changes to their positions in MRUS. Walleye Capital LLC bought a new position in shares of Merus in the 1st quarter worth approximately $619,000. Siren L.L.C. raised its position in Merus by 33.0% in the first quarter. Siren L.L.C. now owns 1,043,467 shares of the biotechnology company's stock worth $43,920,000 after acquiring an additional 259,055 shares during the period. DAFNA Capital Management LLC boosted its stake in shares of Merus by 2.2% during the 1st quarter. DAFNA Capital Management LLC now owns 461,804 shares of the biotechnology company's stock worth $19,437,000 after acquiring an additional 10,000 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its stake in shares of Merus by 99.4% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock worth $141,831,000 after acquiring an additional 1,679,777 shares during the last quarter. Finally, Allostery Investments LP grew its position in shares of Merus by 473.5% during the 1st quarter. Allostery Investments LP now owns 124,657 shares of the biotechnology company's stock valued at $5,247,000 after acquiring an additional 102,922 shares during the period. 96.14% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts recently commented on MRUS shares. Guggenheim reaffirmed a "neutral" rating and set a $97.00 price objective (down from $109.00) on shares of Merus in a research report on Tuesday, September 30th. BMO Capital Markets restated a "market perform" rating and set a $97.00 target price on shares of Merus in a research note on Friday, October 31st. HC Wainwright downgraded shares of Merus from a "buy" rating to a "neutral" rating and dropped their price target for the company from $135.00 to $97.00 in a report on Monday, September 29th. Leerink Partnrs cut shares of Merus from a "strong-buy" rating to a "hold" rating in a report on Sunday, October 5th. Finally, Alliance Global Partners began coverage on shares of Merus in a research report on Monday, August 25th. They set a "buy" rating and a $90.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Merus currently has a consensus rating of "Hold" and an average price target of $93.56.
View Our Latest Analysis on MRUS
Merus Company Profile
(
Get Free Report)
Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company's research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.
The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
